202 related articles for article (PubMed ID: 24927749)
21. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
22. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
23. Activation of p38 MAPK by damnacanthal mediates apoptosis in SKHep 1 cells through the DR5/TRAIL and TNFR1/TNF-α and p53 pathways.
Lin FL; Hsu JL; Chou CH; Wu WJ; Chang CI; Liu HJ
Eur J Pharmacol; 2011 Jan; 650(1):120-9. PubMed ID: 20951126
[TBL] [Abstract][Full Text] [Related]
24. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation.
Chen JJ; Chou CW; Chang YF; Chen CC
J Immunol; 2008 Jun; 180(12):8030-9. PubMed ID: 18523266
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
27. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo.
Kuribayashi K; Finnberg N; Jeffers JR; Zambetti GP; El-Deiry WS
Cell Cycle; 2011 Jul; 10(14):2380-9. PubMed ID: 21709442
[TBL] [Abstract][Full Text] [Related]
28. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
[TBL] [Abstract][Full Text] [Related]
29. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Fandy TE; Shankar S; Ross DD; Sausville E; Srivastava RK
Neoplasia; 2005 Jul; 7(7):646-57. PubMed ID: 16026644
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis).
Wang Z; Zhang X; Luo Y; Song Y; Xiang C; He Y; Wang K; Yu Y; Wang Z; Peng W; Ding Y; Liu S; Wu C
Cell Death Dis; 2024 May; 15(5):375. PubMed ID: 38811536
[TBL] [Abstract][Full Text] [Related]
31. 1,25(OH)
Huang J; Yang G; Huang Y; Zhang S
Biochimie; 2018 Mar; 146():28-34. PubMed ID: 29158005
[TBL] [Abstract][Full Text] [Related]
32. Calotropin from Asclepias curasavica induces cell cycle arrest and apoptosis in cisplatin-resistant lung cancer cells.
Mo EP; Zhang RR; Xu J; Zhang H; Wang XX; Tan QT; Liu FL; Jiang RW; Cai SH
Biochem Biophys Res Commun; 2016 Sep; 478(2):710-5. PubMed ID: 27498029
[TBL] [Abstract][Full Text] [Related]
33. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.
Hirai S; Endo S; Saito R; Hirose M; Ueno T; Suzuki H; Yamato K; Abei M; Hyodo I
PLoS One; 2014; 9(7):e102831. PubMed ID: 25033286
[TBL] [Abstract][Full Text] [Related]
35. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
36. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
[TBL] [Abstract][Full Text] [Related]
37. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
Rojas EA; Corchete LA; San-Segundo L; Martínez-Blanch JF; Codoñer FM; Paíno T; Puig N; García-Sanz R; Mateos MV; Ocio EM; Misiewicz-Krzeminska I; Gutiérrez NC
Clin Cancer Res; 2017 Nov; 23(21):6602-6615. PubMed ID: 28790111
[No Abstract] [Full Text] [Related]
38. GRAMD4 mimics p53 and mediates the apoptotic function of p73 at mitochondria.
John K; Alla V; Meier C; Pützer BM
Cell Death Differ; 2011 May; 18(5):874-86. PubMed ID: 21127500
[TBL] [Abstract][Full Text] [Related]
39. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A; Villunger A; Marschitz I; Kos M; Hittmair A; Lukas P; Grünewald K; Greil R
Br J Haematol; 1997 May; 97(2):418-28. PubMed ID: 9163609
[TBL] [Abstract][Full Text] [Related]
40. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
